1. Home
  2. BIRK vs ROIV Comparison

BIRK vs ROIV Comparison

Compare BIRK & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birkenstock Holding plc

BIRK

Birkenstock Holding plc

HOLD

Current Price

$41.84

Market Cap

8.8B

Sector

N/A

ML Signal

HOLD

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$21.87

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRK
ROIV
Founded
1774
2014
Country
United Kingdom
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8B
14.1B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
BIRK
ROIV
Price
$41.84
$21.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
8
Target Price
$64.69
$24.31
AVG Volume (30 Days)
2.9M
8.2M
Earning Date
02-19-2026
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
83.10
N/A
EPS
2.19
N/A
Revenue
$2,460,904,611.00
$20,329,000.00
Revenue This Year
$14.52
N/A
Revenue Next Year
$14.40
$741.42
P/E Ratio
$18.66
N/A
Revenue Growth
16.22
N/A
52 Week Low
$38.16
$8.73
52 Week High
$62.66
$23.47

Technical Indicators

Market Signals
Indicator
BIRK
ROIV
Relative Strength Index (RSI) 47.12 56.28
Support Level $40.68 $21.36
Resistance Level $43.02 $22.72
Average True Range (ATR) 1.70 0.72
MACD -0.39 -0.13
Stochastic Oscillator 23.86 32.69

Price Performance

Historical Comparison
BIRK
ROIV

About BIRK Birkenstock Holding plc

Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. It sells its products through two main channels: business-to-business (B2B) which comprises sales made to established third-party store networks, and direct-to-consumer (DTC) which comprises sales made on globally owned online stores through the Birkenstock.com domain and sales made in Birkenstock retail stores. The company's reportable segments are based on its regional hubs and include: the Americas which is also its key revenue-generating segment; Europe; and Australia, Japan, India, China, and the United Arab Emirates (APMA).

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: